How to Buy Capricor Therapeutics Stock
Capricor Therapeutics Inc
Capricor Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders.
Capricor Therapeutics stock last closed at $13.03, down 1.88% from the previous day, and has increased 153.01% in one year. It has overperformed other stocks in the Biotechnology industry by 2.31 percentage points. Capricor Therapeutics stock is currently +270.17% from its 52-week low of $3.52, and -44.32% from its 52-week high of $23.40.
There are currently 45.68M shares of CAPR outstanding. The market cap of CAPR is $595.16M. In the past 24 hours, 935,039 CAPR shares were traded.
How to Buy Capricor Therapeutics Stock
Not sure how to invest in Capricor Therapeutics stock? Here's how.
- Decide where to buy Capricor Therapeutics stock: You need to choose a stock brokerage, but don't worry - we've analyzed dozens of stock brokerages and apps to help you choose where to buy Capricor Therapeutics stock.
- Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Deposit money your brokerage account: Select your method of payment and add your information.
- Evaluate Capricor Therapeutics stock: The Capricor Therapeutics ticker symbol is CAPR. Is Capricor Therapeutics stock a good investment? Should you buy shares of CAPR? How do CAPR's underlying business fundamentals look? Do top analysts think Capricor Therapeutics is a good buy? Why has CAPR's stock price moved recently? (Hint: Our stock market analysis tools can help you evaluate if CAPR is a good stock to buy).
- Make your CAPR trade: Decide if you will purchase CAPR shares at the current market price or use a limit order to purchase CAPR shares at a given price.
- Get notifications regarding your investment in CAPR: Create a watchlist to get live updates on your new investment in Capricor Therapeutics shares.
Step 1: Decide where to buy Capricor Therapeutics stock
You need a brokerage account to access the NASDAQ market and buy CAPR shares.
Our preferred brokerage: eToro
We believe that eToro is the best online stock brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
- Access to world financial markets: From Tech to Healthcare, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading stock exchanges.
- Social investing: eToro offers a community with more than 20 million users globally. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've selected the right brokerage, it's time to fill out some personal information so you are able to buy CAPR today.
How to Create a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal data to start a new brokerage account.
- Submit your information by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit money your brokerage account
Now that you have opened your account on one of the most highly reviewed stock apps, you need to deposit funds:
Check out this video walkthrough to see the process of transferring funds into your investment account.
Step 4: Evaluate Capricor Therapeutics stock
Once you have selected the best place to buy Capricor Therapeutics stock, it's absolutely critical to evaluate their stock prior to investing, so you truly understand the risk and upside.
Capricor Therapeutics Metrics
CAPR Due Diligence Checks
WallStreetZen was designed to help part-time investors do more in-depth fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on CAPR's stock page.
Is CAPR stock properly valued?
Investors use many financial metrics, analyses, models, and charts to gauge CAPR's true value.
Using relative valuations ratios:
- CAPR could be undervalued based on its P/B ratio of 4.09x, relative to Biotechnology industry P/B ratio of 4.26x
You can do more valuation analysis on CAPR's stock here.
A quick look at CAPR Financials
Pros:
- CAPR has a low debt to equity ratio of 0.17.
- There are more short-term assets than long-term liabilities on the CAPR balance sheet.
- Total CAPR debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than short-term liabilities on the CAPR balance sheet.
- CAPR has cash burn of 41534717. It has sufficient cash and short-term investments to cover this for at least one year.
- CAPR has $151.52M in cash and short term investments. This is enough to cover its annual cash burn of $41.53M.
Cons:
- CAPR profit margin has gone down from -88.5% to -181.7% in the past year.
Is it a good time to buy CAPR stock, according to Wall Street analysts?
Out of 3 Equities analysts who monitor CAPR, the consensus analyst rating on Capricor Therapeutics is a Strong Buy
It's important to note that analyst ratings are not stock recommendations, nor are they financial advice.
You can dig deeper into what analysts are saying on the Capricor Therapeutics stock forecast page.
Metrics for Advanced CAPR Traders
Is CAPR Making Money?
Last year, CAPR revenue was $22.27M. Over the past five year, CAPR's revenue has increased by 85.83% per year. This was faster than the Biotechnology industry average of 45.84%.
Find out more about CAPR's earnings and revenue performance here.
Latest Insiders Trades at CAPR
Over the last 12 months, insiders at CAPR have bought more shares than they have sold.
Anthony Bergmann, CHIEF FINANCIAL OFFICER of CAPR, was the latest CAPR insider to buy. They bought $3,475.00 worth of CAPR stock on Mar 3, 2025.
Research more about who owns CAPR stock here.
Does CAPR provide a stable income stream?
No, Capricor Therapeutics doesn't provide an income stream by paying out dividends.
What others are saying about CAPR
One of the biggest reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Make your CAPR trade
You have two primary options:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are generally fine for most investors. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to be certain you're buying or selling at an exact dollar amount limit, use a limit order.
Press the Open Trade button and your broker will place your order.
If you want additional help investing in stocks on eToro, click the how to video below:
Step 6: Get notifications regarding your investment in CAPR
Now that you own some CAPR stock, you'll want to stay up-to-date on your new company.
Add CAPR to a watchlist to get notified of the latest news about your CAPR stock.
CAPR Feed
How to Buy Stock in Capricor Therapeutics
To reiterate, here are the 6 steps you need to take to buy Capricor Therapeutics stock right now:
- Decide where to buy Capricor Therapeutics stock
- Create your brokerage account
- Deposit money your brokerage account
- Evaluate Capricor Therapeutics stock
- Make your CAPR trade
- Get notifications regarding your investment in CAPR
If you require a place to buy stocks, eToro is our recommended venue.
Get Started with eToro TodayIf you want to keep track of your investment in Capricor Therapeutics, hit the button below to create your watchlist.
More Content You May Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.